Last updated: February 14, 2026
Product Overview
NDC 16571-0676 is a biologic drug marketed as Humira (adalimumab), primarily used for autoimmune conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis. This medication is administered via subcutaneous injection. The drug has multiple formulations; the specific NDC indicates a particular strength and package size.
Market Size and Growth
Humira remains one of the top-selling drugs globally. In 2022, its US sales reached approximately $18 billion, representing a decline from peak sales of about $20 billion in 2021, driven by biosimilar competition. The global biologics market, including adalimumab, was valued at an estimated $330 billion in 2022, with a compound annual growth rate (CAGR) of roughly 8% over the past five years.
Biosimilar Competition
Multiple biosimilars for adalimumab have entered markets internationally since 2021, notably:
- Amgevita (Amgen/AbbVie partnership) and Hyrimoz (Sandoz) launched in multiple regions.
- Cyltezo (Boehringer Ingelheim) and Abrilada (Eli Lilly) as US-approved biosimilars.
- Biosimilars have captured 20-40% of the US market, leading to significant price erosion.
In the US, the introduction of biosimilars has reduced Humira’s list price by approximately 50% since 2021. However, list price reductions do not always translate to equivalent savings for patients and payers due to rebate structures.
Pricing Dynamics and Projections
- Current List Price: The average annual list price for a Humira prefilled syringe is approximately $70,000 - $75,000.
- Rebate-Adjusted Price: Payers often negotiate rebates leading to net prices around $30,000 - $35,000 per year.
- Biosimilar Impact: Biosimilar entry initially caused list price declines of about 20-30%, with further erosion possible as more biosimilars gain approval and market share.
Price Projections (Next 5 Years)
| Year |
Estimated List Price |
Expected Average Net Price |
Market Share (Humira) |
Biosimilar Share |
| 2023 |
$70,000 - $75,000 |
$30,000 - $35,000 |
60% |
40% |
| 2024 |
$68,000 - $73,000 |
$29,000 - $34,000 |
55% |
45% |
| 2025 |
$65,000 - $70,000 |
$28,000 - $33,000 |
50% |
50% |
| 2026 |
$63,000 - $68,000 |
$27,000 - $32,000 |
45% |
55% |
| 2027 |
$60,000 - $65,000 |
$25,000 - $30,000 |
40% |
60% |
The list price may continue to decline marginally, driven by patent cliffs, increasing biosimilar competition, and payer negotiations. Net prices are likely to stabilize or decline further as rebates and negotiations evolve.
Patent and Regulatory Landscape
- The original Humira patent expired in the US in January 2023.
- Multiple biosimilar competitors now market in the US, driving price reductions.
- As patent litigations resolve, more biosimilars are expected to launch, further pressuring pricing.
Market Opportunities and Risks
- Biologics like Humira face imminent biosimilar competition, constraining revenue growth.
- New indications and formulations (e.g., auto-injectors, prefilled syringes) could offset some revenue declines.
- Entering the biosimilar or biosimilar-adjacent market with innovations could provide growth avenues.
Summary
NDC 16571-0676, representing Humira, remains commercially significant despite biosimilar pressure. The next five years will see continued price erosion but stable demand due to its entrenched therapeutic position. Pricing will depend heavily on biosimilar market penetration, negotiated rebates, and potential pipeline innovations.
Key Takeaways
- Humira continues to dominate the biologics market but faces substantial biosimilar competition since patent expiry in 2023.
- Price reductions and volume shifts driven by biosimilars are expected to reduce net revenue margins.
- List prices are likely to decline marginally over the next five years, with net prices stabilized through rebates.
- Market share for biosimilars is expected to grow to approximately 60% by 2027.
- Regulatory, legal, and competitive factors will influence future pricing and market dynamics.
FAQs
1. How will biosimilar entries impact Humira’s market share?
Biosimilars are expected to capture up to 60% of the US market by 2027, driven by price competition and formulary preferences.
2. What is the primary driver of price reduction for Humira?
Biosimilar competition following patent expiry, along with negotiated rebates and formulary positioning.
3. Will the list price of Humira continue to decline?
Yes, due to biosimilar competition and patent challenges; however, the drop is expected to slow as the market stabilizes.
4. How significant are biosimilar rebates for net pricing?
Rebates can reduce the effective net price by 50% or more, heavily influencing revenue despite stable list prices.
5. Are new formulations or indications expected to offset revenue declines?
Potentially. Expanded indications, auto-injectors, and other formulations can help retain market share and revenue.
Citations
- IQVIA, "United States Biologics Market Data," 2022.
- Evaluate Pharma, "Global Biologics Market Forecast," 2022.
- FDA, "Biosimilar Approvals," 2022.
- Bloomberg Intelligence, "Biologic Drug Pricing Dynamics," 2022.
- U.S. Patent and Trademark Office, "Humira Patent Timeline," 2023.
